Safety and efficacy of eculizumab in ...

Document type :
Article dans une revue scientifique
DOI :
10.1016/S1474-4422(17)30369-1
PMID :
29066163
Permalink :
http://hdl.handle.net/20.500.12210/4934
Title :
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
Author(s) :
Howard James, F [Auteur]
Utsugisawa, Kimiaki [Auteur]
Benatar, Michael [Auteur]
Murai, Hiroyuki [Auteur]
Barohn Richard, J [Auteur]
Illa, Isabel [Auteur]
Jacob, Saiju [Auteur]
Vissing, John [Auteur]
Burns Ted, M [Auteur]
Kissel John, T [Auteur]
Muppidi, Srikanth [Auteur]
Nowak Richard, J [Auteur]
O''brien, Fanny [Auteur]
Wang, Jing [Auteur]
Mantegazza, Renato [Auteur]
Journal title :
The Lancet. Neurology
Abbreviated title :
Lancet Neurol.
Volume number :
16
Pages :
976-986
Publication date :
2017-12-01
ISSN :
1474-4465
1474-4465
Keyword(s) :
Mesh:Drug Resistance
Mesh:Myasthenia Gravis/physiopathology
Mesh:Antibodies
Mesh:Monoclonal
Mesh:Humanized/adverse effects
Mesh:Outcome Assessment (Health Care)*
Mesh:Humans
Mesh:Receptors
Mesh:Cholinergic/immunology*
Mesh:Aged
Mesh:Double-Blind Method
Mesh:Male
Mesh:Antibodies
Mesh:Monoclonal
Mesh:Humanized/pharmacology*
Mesh:Antibodies
Mesh:Monoclonal
Mesh:Humanized/administration & dosage
Mesh:Adult
Mesh:Female
Mesh:Severity of Illness Index*
Mesh:Middle Aged
Mesh:Autoantibodies/blood*
Mesh:Myasthenia Gravis/blood
Mesh:Myasthenia Gravis/drug therapy*
HAL domain(s) :
Sciences du Vivant [q-bio]
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
Inserm
Université de Lille
CHU Lille
Collections :
Research team(s) :
Immunity, inflammation and fibrsis in auto and allo-reactivity
Submission date :
2019-03-01T14:26:47Z